Table 2.
Changes in rheumatoid arthritis patients treated with Tofacitinib for 6 months.
| Patients | M0N = 9 | M6N = 9 | Absolute difference | P-value |
|---|---|---|---|---|
| Body mass index, kg/m² | 25.9 (3.4) | 26.1 (6.3) | +0.2 | 0.64 |
| Handgrip test, kg | 22.5 (8.9) | 27.9 (14.0) | +5.4 | 0.01 |
| IPAQ-SF, MET-min/week | 6,203 (8,461) | 7,110 (4,111) | +907 | 0.49 |
| Body Fat Percentage, % | 3939.4 (8.5) | 39.4 (9.0) | 0 | 0.46 |
| Appendicular lean mass, kg | 16.6 (4.5) | 16.7 (4.9) | +0.1 | 0.50 |
| Visceral Adipose Tissue, cm² | 150 (81) | 173 (88) | +23 | 0.18 |
| Lumbar spine BMD, g/cm² | 1.011 (0.142) | 0.996 (0.146) | −0.015 | 0.058 |
| Femoral neck BMD, g/cm² | 0.728 (0.108) | 0.713 (0.095) | −0.015 | 0.30 |
| Total hip BMD, g/cm² | 0.902 (0.130) | 0.891 (0.105) | −0.011 | 0.82 |
| Lumbar spine PDFF (%) | 46.3 (7.0) | 53.2 (9.2) | +6.9 | 0.008 |
| CTX, pmol/L | 3,503 (1,830) | 2,712 (2,196) | −791 | 0.91 |
| Leptine, ng/L | 14.9 (19.7) | 19.4 (24.9) | +4.5 | 0.30 |
Data reported as mean (Standard Deviation) unless otherwise indicated. CTX , Cross laps; DAS, Disease Activity Score; IPAQ-SF, International Physical Activity Questionnaire—Short Form; MET, Metabolic Equivalent of Task; PDFF, Proton Density Fat Fraction. Bold values mean statistically significant.